Stockscreener 앱 받기
3.13
0.97%
0.03
시간 외 거래:
3.12
-0.010
-0.32%
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Will Fortress Biotech Inc outperform during market ralliesTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Gap Down: Will Fortress Biotech Inc outperform during market ralliesNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Discipline and Rules-Based Execution in FBIOP Response - Stock Traders Daily
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Yahoo Finance
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Fortress Biotech’s (FBIO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biot - GuruFocus
FBIO Eyes Future Growth Amid Financial Optimism - StocksToTrade
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus
Fortress Biotech Inc. Shares Soar After Promising New Developments - timothysykes.com
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Fortress Biotech: PRV Windfall and De-Risked Zycubo Economics Support Buy Rating and $17 Target - TipRanks
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M - GuruFocus
Fortress Biotech Inc. Faces Stock Volatility Amid Strategic Adjustments - StocksToTrade
Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics - GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Yahoo Finance
Strategic Acquisition Sends Fortress Biotech Stocks Soaring - timothysykes.com
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - marketscreener.com
Cyprium Voucher Sale Bolsters Fortress Biotech Liquidity - TipRanks
Fortress Biotech Monetizes PRV for $205 Million; Amends Oaktree Credit Facility - TradingView
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Gains Recap: What is Fortress Biotech Incs revenue forecastEarnings Performance Report & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Insider Trends: Can SVIIU navigate macro headwindsJuly 2025 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened - Defense World
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Trade Report: Is Fortress Biotech Inc part of any ETFDividend Hike & Low Volatility Stock Recommendations - baoquankhu1.vn
MSN Money - MSN
Fortress Biotech amends credit agreement with Oaktree - MSN
Behavioral Patterns of FBIOP and Institutional Flows - Stock Traders Daily
What is Fortress Biotech Inc.’s book value per shareJuly 2025 Update & Reliable Intraday Trade Plans - mfd.ru
Does Fortress Biotech Inc. stock benefit from AI growthJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Does Fortress Biotech Inc. stock reflect fundamentals2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
Will Fortress Biotech Inc. stock recover faster than peers2025 Market Overview & Intraday High Probability Alerts - mfd.ru
Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment () - aktiencheck.de
Wall Street Recap: How do insiders feel about Fortress Biotech IncDividend Hike & Trade Opportunity Analysis - baoquankhu1.vn
Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28% - 富途牛牛
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Jump Above Average Bulls Prepare For Follow Through - Kalkine Media
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
(FBIOP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Down 4.7% – What’s Next? - Defense World
Fortress Biotech Leads High-Performing Stocks with 93.1% Return - Markets Mojo
Aug Technicals: Can Fortress Biotech Inc deliver alpha2025 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
ETF Watch: How liquid is OS Therapies Incorporated stockIPO Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
How (FBIOP) Movements Inform Risk Allocation Models - Stock Traders Daily
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy - MarketBeat
Analysts Issue Forecasts for FBIO FY2025 Earnings - Defense World
Fortress Bio gains on FDA approval of copper replacement therapy - MSN
Research Analysts Set Expectations for FBIO FY2025 Earnings - MarketBeat
3.69%
0.68%
자본화:
|
볼륨(24시간):